Catalyst
Slingshot members are tracking this event:
Vertex (VRTX) Announces Phase 3 Results Evaluating ORKAMBI in Children 6-11 with Cystic Fibrosis with Two Copies of F508del Mutation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Results, Orkambi, Children, 6-11, Cystic Fibrosis, F508del Mutation, Two Copies
